PPD recognized for leadership in clinical research
Pharmaceutical Product Development (PPD) has been recognized for excellence in clinical research by pharmaceutical and biotechnology executives surveyed for Life Science Leader magazine’s 2017 CRO Leadership Awards.
PPD earned high honors in all of the five distinct categories: capabilities, compatibility, expertise, quality and reliability. The results are based on survey responses from biopharmaceutical industry leaders responsible for making or influencing decisions to collaborate with CROs on clinical development programs.
PPD’s comprehensive offerings range from integrated early development through post-market services and PPD Laboratories, offering the most comprehensive lab services available in the industry.
“PPD is committed to accelerating the generation of evidence necessary for our customers to bring life-changing therapies to society,” said David Simmons, chairman and CEO of PPD. “Pharmaceutical and biotechnology clients can rely on our expertise and tailored, quality-first services across phase I-IV and post-approval research, with integrated and comprehensive laboratory services and industry leadership in site and patient relationships. Our strategically expanded service offerings help ensure our clients’ evolving needs are met with precision and high quality across the drug development continuum.”
The survey for the 2017 CRO Leadership Awards, which encompassed 27 performance metrics, was conducted by Industry Standard Research, a full-service pharmaceutical market research firm, to help Life Science Leader assess the performance of CROs.
Upcoming Events
-
21Oct